SEPIA ACS-TIMI 42

SEPIA-ACS-TIMI 42 evaluated the efficacy and safety of otamixaban, a direct factor Xa inhibitor, in patients with non-ST-elevation acute coronary syndrome. MAIN RESULTS: Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial Lancet. 2009 Sep 5;374(9692):787-95. PRESENTATIONS TIMI 42 Slides OTHER PUBLICATIONS Prognostic … Continue reading SEPIA ACS-TIMI 42